Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho to Start New Project to Help Development of New Immunosuppression Therapies
September 27, 2004
- Chugai to Drastically Reorganize Marketing System in October
September 27, 2004
- Prefectural Gov'ts Asked to Prepare for Flu Season
September 27, 2004
- Formulation Research Committees of PMAT, OPMA Merge Under Aegis of JPMA
September 27, 2004
- CDFS Task Force to Draft New GL on Use of Blood Products
September 27, 2004
- Strategic Health Care Industry Reform Conference
September 27, 2004
- REGULATORY NEWS IN BRIEF
September 27, 2004
- Modifications of Azwell's, Fukujin's Business Reconstruction Plan Approved
September 27, 2004
- Japanese Healthcare Q&A (11)
September 27, 2004
- MOSS Institute Aims to Make Comeback via EDC Business
September 27, 2004
- 61.2% of JMHA Hospitals Recorded Deficits in FY2003: Survey
September 27, 2004
- BUSINESS NEWS IN BRIEF
September 27, 2004
- Proper Use of Anti-cancer Drugs with Add'l Indications Called For
September 27, 2004
- Group to Promote Standardized Cancer Therapy Holds 1st Meeting
September 27, 2004
- 60% of Respondents Support Acceptance of Qualified Foreign Nurses: Survey
September 27, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
September 27, 2004
- MEDICAL DEVICE NEWS IN BRIEF
September 27, 2004
- DIAGNOSTIC NEWS IN BRIEF
September 27, 2004
- WORLD NEWS IN BRIEF
September 27, 2004
- GSK to Broadcast Educational Drama on Depression via Web
September 27, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…